探索预测索拉菲尼治疗晚期原发性肝细胞癌疗效的分子标志物的研究.doc 全文

  本文关键词：探索预测索拉菲尼治疗晚期原发性肝细胞癌疗效的分子标志物的研究，由笔耕文化传播整理发布。

探索预测索拉菲尼治疗晚期原发性肝细胞癌疗效的分子标志物的研究 赵 鹏1，陈 东2，，陈 伟2，殷晓煜2， 梁力建2 （536003 贵州 遵义，遵义医学院附属第一医院肝胆外科1； 510080广州，中山大学附属第一医院肝胆外科2） [摘要] 目的 探索可能预测索拉菲尼治疗晚期原发性肝细胞癌 epatocellular carcinoma,HCC 疗效的分子标志物。方法 回顾性分析应用索拉菲尼治疗的54例晚期HCC患者临床资料，将索拉菲尼治疗前病理组织切片分别以抗体VEGFR、pERK、pS6K、PTEN进行免疫组组织化学染色（IHC），根据各抗体染色结果的不同分为高表达组和低表达组，结合索拉菲尼治疗后的疾病进展时间（time to progression, TTP） VEGFR、pERK高表达组较低表达组的TTP明显延长（P＜0.05），PS6K两组之间的TTP无显著差异（P＞0.05）PTEN几乎无阳性表达To investigate the candidate molecular markers for predicting the efficacy of sorafenib in treating with advanced HCC Zhao Peng1, Chen Dong 2, Chen Wei2, 2Yin Xiaoyu, 2Liang Lijian 1Department of Hepatobiliary Surgery, the First Affiliated Hospital of ZunYi Medical College, ZunYi, 536003, China. 2Department of hepatobiliary surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,510080, China. Corresponding author LIANG Li-jian ,E-mail:[email protected] [Abstract] Objective To investigate the candidate molecular markers for predicting the efficacy of sorafenib in treating with advanced HCC.Methods In this retrospective study , 54 advanced HCC patients were given sorafenib 400mg twice a day and the time to progression TTP were recorded. Sections cut from paraffin-embedded liver tumor biopsies from the 54 patients which were obtained before sorafenib treatment were analyzed with immunohistochemistry staining IHC using rabbit polyclonal antibodies for phosphorylated extracellular signal regulated kinase p

  本文关键词：探索预测索拉菲尼治疗晚期原发性肝细胞癌疗效的分子标志物的研究，由笔耕文化传播整理发布。